Atypical diabetes associated with inclusion formation in the R6/2 mouse model of Huntington's disease is not improved by treatment with hypoglycaemic agents

Experimental Brain Research

Volumn 166, Issue 2, 2005, Pages 220-229

  Hunt, Mark J ^a   Morton, A Jennifer ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Diabetes; Glibenclamide; Glycosuria; Huntington's disease; Rosiglitazone

Indexed keywords

ANTIDIABETIC AGENT; GLIBENCLAMIDE; INSULIN; ROSIGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INCLUSION; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFECT; EXOCYTOSIS; HUNTINGTON CHOREA; INSULIN RELEASE; INSULIN SENSITIVITY; MOTOR DYSFUNCTION; MOUSE; NEUROLOGIC DISEASE; NONHUMAN; PANCREAS ISLET BETA CELL; PHENOTYPE; PRIORITY JOURNAL; SENSITIZATION; SURVIVAL; TRANSGENIC MOUSE;

ADMINISTRATION, ORAL; ANIMALS; BEHAVIOR, ANIMAL; DIABETES MELLITUS; DISEASE MODELS, ANIMAL; EXOCYTOSIS; GLUCOSE INTOLERANCE; GLYBURIDE; GLYCOSURIA; HUNTINGTON DISEASE; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, NEUROLOGIC MUTANTS; MICE, TRANSGENIC; THIAZOLIDINEDIONES;

EID: 26044473385     PISSN: 00144819     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00221-005-2357-z     Document Type: Article

References (48)

1. Abderrahmani A, Niederhauser G, Plaisance V, Roehrich ME, Lenain V, Coppola T, Regazzi R, Waeber G (2004) Complexin I regulates glucose-induced secretion in pancreatic beta-cells. J Cell Sci 117:2239-2247
2. Andreassen OA, Dedeoglu A, Stanojevic V, Hughes DB, Browne SE, Leech CA, Ferrante RJ, Habener JF, Beal MF, Thomas MK (2002) Huntington's disease of the endocrine pancreas: insulin deficiency and diabetes mellitus due to impaired insulin gene expression. Neurobiol Dis 11:410-424
3. Armario A, Martí J, Gil M (1990) The serum glucose response to acute stress is sensitive to the intensity of the stressor and to habituation. Psychoneuroendocrinology 15:341-347
4. Ashcroft SJ, Ashcroft FM (1992) The sulfonylurea receptor. Biochim Biophys Acta 1175:45-59
5. Bjorkqvist M, Fex M, Renstrom E, Wierup N, Petersen A, Gil J, Bacos K, Popovic N, Li JY, Sundler F, Brundin P, Mulder H (2005) The R6/2 transgenic mouse model of Huntington's disease develops diabetes due to deficient beta-cell mass and exocytosis. Hum Mol Genet 14:565-574
6. Brackenridge CJ (1979) Relation of occupational stress to the age at onset of Huntington's disease. Acta Neurol Scand 60:272-276
7. Carter RJ, Lione LA, Humby T, Mangiarini L, Mahal A, Bates GP, Dunnett SB, Morton AJ (1999) Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J Neurosci 19:3248-3257
8. Carter RJ, Hunt MJ, Morton AJ (2000) Environmental stimulation increases survival in mice transgenic for exon 1 of the Huntington's disease gene. Mov Disord 15:925-937
9. Cha JH, Kosinski CM, Kerner JA, Alsdorf SA, Mangiarini L, Davies SW, Penney JB, Bates GP, Young AB (1998) Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene. Proc Natl Acad Sci USA 95:6480-6485
10. Connor SC, Hughes MG, Moore G, Lister CA, Smith SA (1997) Antidiabetic efficacy of BRL 49653, a potent orally active insulin sensitizing agent, assessed in the C57BL/KsJ db/db diabetic mouse by non-invasive 1H NMR studies of urine. J Pharm Pharmacol 49:336-344
11. Craft S, Watson GS (2004) Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 3(3):169-178
12. De Boer SF, Koopmans SJ, Slangen JL, Van der Gugten J (1990) Plasma catecholamine, corticosterone and glucose responses to repeated stress in rats: effect of interstressor interval length. Physiol Behav 4:1117-1124
13. Durant S, Christeff N, Coulaud J, Nunez EA, Dardenne M, Homo-Delarche F (1998) Basal concentrations of various steroids in the nonobese diabetic (NOD) mouse and effect of immobilization stress. Autoimmunity 28:249-258
14. Evans JL, Goldfine ID, Maddux BA, Grodsky GM (2002) Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 23:599-622
15. Fain JN, Del Mar NA, Meade CA, Reiner A, Goldowitz D (2001) Abnormalities in the functioning of adipocytes from R6/2 mice that are transgenic for the Huntington's disease mutation. Hum Mol Genet 10:145-152
16. Farrer LA (1985) Diabetes mellitus in Huntington disease. Clin Genet 27:62-67
17. Ferrante RJ, Andreassen OA, Jenkins BG, Dedeoglu A, Kuemmerle S, Kubilus JK, Kaddurah-Daouk R, Hersch SM, Beal MF (2000) Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J Neurosci 20:4389-4397
18. Fuhlendorff J, Rorsman P, Kofod H, Brand CL, Rolin B, MacKay P, Shymko R, Carr RD (1998) Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 47(3):345-351
19. Glass M, van Dellen A, Blakemore C, Hannan AJ, Faull RL (2004). Delayed onset of Huntington's disease in mice in an enriched environment correlates with delayed loss of cannabinoid CB1 receptors. Neuroscience 123(1):207-212
20. Goodyear LJ, Kahn BB (1998) Exercise, glucose transport, and insulin sensitivity. Annu Rev Med 49:235-261
21. Henriksen EJ (2002) Invited review: effects of acute exercise and exercise training on insulin resistance. J Appl Physiol 93:788-796
22. Ho FM, Liu SH, Liau CS, Huang PJ, Lin-Shiau SY (2000) High glucose-induced apoptosis in human endothelial cells is mediated by sequential activations of c-Jun NH(2)-terminal kinase and caspase-3. Circulation 101:2618-2624
23. Hockly E, Cordery PM, Woodman B, Mahal A, van Dellen A, Blakemore C, Lewis CM, Hannan AJ, Bates GP (2002) Environmental enrichment slows disease progression in R6/2 Huntington's disease mice. Ann Neurol 51(2):235-242
24. Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72:971-983
25. Hurlbert MS, Zhou W, Wasmeier C, Kaddis FG, Hutton JC, Freed CR (1999) Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes. Diabetes 48:649-651
26. Jenkins BG, Klivenyi P, Kustermann E, Andreassen OA, Ferrante RJ, Rosen BR, Beal MF (2000) Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice. J Neurochem 74(5):2108-2119
27. Jucker BM, Schaeffer TR, Haimbach RE, McIntosh TS, Chun D, Mayer M, Ohlstein DH, Davis HM, Smith SA, Cobitz AR, Sarkar SK (2002) Normalization of skeletal muscle glycogen synthesis and glycolysis in rosiglitazone-treated Zucker fatty rats: an in vivo nuclear magnetic resonance study. Diabetes 51(7):2066-2073
28. Lione LA, Carter RJ, Hunt MJ, Bates GP, Morton AJ, Dunnett SB (1999) Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation. J Neurosci 19:10428-10437
29. Liu YF (1998) Expression of polyglutamine-expanded Huntingtin activates the SEK1-JNK pathway and induces apoptosis in a hippocampal neuronal cell line. J Biol Chem 273:28873-28877
30. Luesse HG, Schiefer J, Spruenken A, Puls C, Block F, Kosinski CM (2001) Evaluation of R6/2 HD transgenic mice for therapeutic studies in Huntington's disease: behavioral testing and impact of diabetes mellitus. Behav Brain Res 126:185-195
31. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, Bates GP (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87:493-506
32. Miller TW, Shirley TL, Wolfgang WJ, Kang X, Messer A (2003) DNA vaccination against mutant huntingtin ameliorates the HDR6/2 diabetic phenotype. Mol Ther 7(5 Pt 1):572-579
33. Morton AJ, Edwardson JM (2001) Progressive depletion of complexin II in a transgenic mouse model of Huntington's disease. J Neurochem 76:166-172
34. Morton AJ, Lagan MA, Skepper JN, Dunnett SB (2000) Progressive formation of inclusions in the striatum and hippocampus of mice transgenic for the human Huntington's disease mutation. J Neurocytol 29:679-702
35. Nakai N, Miyazaki Y, Sato Y, Oshida Y, Nagasaki M, Tanaka M, Nakashima K, Shimomura Y (2002) Exercise training increases the activity of pyruvate dehydrogenase complex in skeletal muscle of diabetic rats. Endocr J 49:547-554
36. Podolsky S, Leopold NA (1977) Abnormal glucose tolerance and arginine tolerance tests in Huntington's disease. Gerontology 23:55-63
37. Podolsky S, Leopold NA, Sax DS (1972) Increased frequency of diabetes mellitus in patients with Huntington's chorea. Lancet 1:1356-1358
38. Ribchester RR, Thomson D, Wood NI, Hinks T, Gillingwater TH, Wishart TM, Court FA, Morton AJ (2004) Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation. Eur J Neurosci 20:3092-3114
39. Sathasivam K, Hobbs C, Turmaine M, Mangiarini L, Mahal A, Bertaux F, Wanker EE, Doherty P, Davies SW, Bates GP (1999) Formation of polyglutamine inclusions in non-CNS tissue. Hum Mol Genet 8:813-822
40. Schubotz R, Hausmann L, Kaffarnik H, Zehner J, Oepen H (1976) Fatty acid patterns and glucose tolerance in Huntington's chorea (author's transi). Res Exp Med (Berl) 167:203-215
41. Squitieri F, Cannella M, Simonelli M (2002) CAG mutation effect on rate of progression in Huntington's disease. Neurol Sci 23(Suppl 2):S107-108
42. Surwit RS, McCubbin JA, Livingston EG, Feinglos MN (1985) Classically conditioned hyperglycemia in the obese mouse. Psychosom Med 47:565-568
43. Surwit RS, McCubbin JA, Kuhn CM, McGee D, Gerstenfeld D, Feinglos MN (1986) Alprazolam reduces stress hyperglycemia in ob/ob mice. Psychosom Med 48:278-282
44. Surwit RS, Schneider MS, Feinglos MN (1992) Stress and diabetes mellitus. Diabetes Care 15:1413-1422
45. Trube G, Rorsman P, Ohno-Shosaku T (1986) Opposite effects of tolbutamide and diazoxide on the ATP-dependent K+ channel in mouse pancreatic beta-cells. Pflugers Arch 407:493-499
46. Wolffenbuttel BH, Gomis R, Squatrito S, Jones NP, Patwardhan RN (2000) Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients. Diabet Med 17(1):40-47
47. Yasuda S, Inoue K, Hirabayashi M, Higashiyama H, Yamamoto Y, Fuyuhiro H, Komure O, Tanaka F, Sobue G, Tsuchiya K, Hamada K, Sasaki H, Takeda K, Ichijo H, Kakizuka A (1999) Triggering of neuronal cell death by accumulation of activated SEK1 on nuclear polyglutamine aggregations in PML bodies. Genes Cells 4:743-756
48. Young PW, Cawthorne MA, Coyle PJ, Holder JC, Holman GD, Kozka IJ, Kirkham DM, Lister CA, Smith SA (1995) Repeat treatment of obese mice with BRL 49653, a new potent insulin sensitizer, enhances insulin action in white adipocytes. Association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling. Diabetes 44:1087-1092